Stocktoria
Nuo Therapeutics, Inc. AURX
OTC · OOTC · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2017-01-19
Nuo Therapeutics, Inc. (AURX) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $3.3M at a -75.8% net margin.
3/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Price from month-end closes (Yahoo) — for reference, not real-time.
Market cap$49M
Net margin-75.8%
Revenue trend · last 10y · down
How it ranks in Manufacturing · percentile among 1829 companies
Piotroski Fstronger than 26%
Net marginstronger than 24%
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Detailed pages
Sector peers · similar-size Manufacturing companies
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| AURX | Nuo Therapeutics, Inc. | 3/9 | — | — | — |
| INBS | INTELLIGENT BIO SOLUTIONS INC. | 2/9 | — | — | — |
| OSRH | OSR Health, Inc. | 0/9 | 1.04 | — | — |
| USAQ | QHSLab, Inc. | 5/9 | -1.02 | 8.1 | — |
| TNON | Tenon Medical, Inc. | 4/9 | — | — | — |
| FEMY | FEMASYS INC | 2/9 | — | — | — |
| LUCD | Lucid Diagnostics Inc. | 3/9 | — | — | — |
FAQ
Is AURX financially healthy?
Nuo Therapeutics, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does AURX pay a dividend?
No, Nuo Therapeutics, Inc. does not currently pay a dividend.
How profitable is AURX?
In FY2025, Nuo Therapeutics, Inc. had a net margin of -75.8%.
Source: SEC EDGAR filings · CIK 0001091596 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.